Luspatercept: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) recommended or restricted luspatercept, while AOTMIT (Poland), AWMSG (Wales) and NYE METODER (Norway) did not recommend it.
The record spans 4.8 years, opening at AWMSG (Wales) on 2 Feb 2021 and running to 5 Nov 2025.
CIPM (Spain) changed its position: not recommended on 2 Jun 2022, recommended by 24 Jul 2023, after a resubmission.
No assessment is on file from PBAC (Australia), SMC (Scotland), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for luspatercept, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 11 of 22 records date from 2023 or later.
Against its own class, luspatercept is an outlier: 29% of its decisive outcomes were positive, where molecules sharing ATC class B03X average 64%.
3 distinct indication wordings are recorded for luspatercept by the agencies that label one in English (AWMSG and NICE).
AWMSG (Wales) was first to assess luspatercept, on 2 Feb 2021; CHUIKYO (Japan) did not open a file until 10 Apr 2024 — a wide spread of 3.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
7 of the 9 agencies here assessed luspatercept more than once, G-BA (Germany) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for luspatercept.
The full ledger for luspatercept reads 10 not recommended, 4 recommended, 4 no benefit and 2 terminated, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 27 Apr 2025 | Behandling av voksne med transfusjonsavhengig anemi pga. svært lav, lav og middels risiko myelodysplastiske syndromer (M… | decision recorded | source |
| AOTMIT (Poland) | 26 Mar 2025 | Reblozyl reimbursement recommendation | not recommended | source |
| G-BA (Germany) | 17 Oct 2024 | Reblozyl — benefit assessment §35a | added benefit: minor (hint) | source |
| CHUIKYO (Japan) | 10 Apr 2024 | レブロジル: cost-effectiveness evaluation (new product, high price or high sales) | evaluation completed, price adjustment decided | source |
| CIPM (Spain) | 24 Jul 2023 | Indicacio nes terapéutica s autorizada s: Reblozyl está indicado para el tratamiento de pacientes adultos con anemia dep… | financed by the SNS, on appeal · art. 92 a, c | source |
17 further decisions for luspatercept, across 8 agencies, are not shown here. They include the most recent record on file, 5 Nov 2025 from HAS (France); its outcome is in the subscriber dataset. They link to 15 further source documents.
Related molecules
- epoetin alfa — same ATC class B03X — Antianemics
- roxadustat — same ATC class B03X — Antianemics
- darbepoetin alfa — same ATC class B03X — Antianemics
- epoetin zeta — same ATC class B03X — Antianemics
- epoetin theta — same ATC class B03X — Antianemics
- cefazolin — also decided by HAS in 2025Q4
Coverage: 22 decisions for luspatercept from 9 agencies, 2021 to 2025. Data to 7 Sep 2026. ATC class B03X — Antianemics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.